A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models.

3D cell culture Matrigel PDX models bladder cells tumor spheroids ultra-low attachment plates

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 May 2020
Historique:
received: 20 04 2020
revised: 16 05 2020
accepted: 19 05 2020
entrez: 28 5 2020
pubmed: 28 5 2020
medline: 28 5 2020
Statut: epublish

Résumé

Patient-derived xenograft (PDX) models allow for personalized drug selection and the identification of drug resistance mechanisms in cancer cells. However, PDX models present technical disadvantages, such as long engraftment time, low success rate, and high maintenance cost. On the other hand, tumor spheroids are emerging as an in vitro alternative model that can maintain the phenotype of cancer cells long enough to perform all assays and predict a patient's outcome. The present work aimed to describe a simple, reproducible, and low-cost 3D in vitro culture method to generate bladder tumor spheroids using human cells from PDX mice. Cancer cells from PDX BL0293 and BL0808 models, previously established from advanced bladder cancer, were cultured in 96-well round-bottom ultra-low attachment (ULA) plates with 5% Matrigel and generated regular and round-shaped spheroids (roundness > 0.8) with a diameter larger than 400 μm and a hypoxic core (a feature related to drug resistance in solid tumors). The responses of the tumor spheroids to the antineoplastic drugs cisplatin, gemcitabine, and their combination were similar to tumor responses in in vivo studies with PDX BL0293 and BL0808 mice. Therefore, the in vitro 3D model using PDX tumor spheroids appears as a valuable tool that may predict the outcome of in vivo drug-screening assays and represents a low-cost strategy for such purpose.

Identifiants

pubmed: 32455634
pii: cancers12051304
doi: 10.3390/cancers12051304
pmc: PMC7281103
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : FAPESP
ID : 2015/05102-1
Organisme : CAPES
ID : 88881.133479/2016-01

Références

J Biotechnol. 2016 Mar 10;221:118-29
pubmed: 26815388
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Biotechnol Lett. 2016 Aug;38(8):1389-95
pubmed: 27167883
Sci Rep. 2017 Sep 25;7(1):12277
pubmed: 28947782
Biotechnol Bioeng. 2003 Jul 20;83(2):173-80
pubmed: 12768623
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5874-9
pubmed: 14676109
Oncogene. 2017 Jan 26;36(4):439-445
pubmed: 27345407
PLoS One. 2014 Aug 13;9(8):e103817
pubmed: 25119185
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484
PLoS One. 2017 Jul 13;12(7):e0181340
pubmed: 28704566
Nat Rev Cancer. 2015 Dec;15(12):747-56
pubmed: 26536825
Cell. 2018 Apr 5;173(2):515-528.e17
pubmed: 29625057
Cancer Res. 2018 Aug 1;78(15):4370-4385
pubmed: 29891506
J Exp Clin Cancer Res. 2017 Aug 3;36(1):102
pubmed: 28774341
Biol Open. 2019 Jan 24;8(1):
pubmed: 30578251
J Hematol Oncol. 2020 Jan 7;13(1):4
pubmed: 31910904
Sci Rep. 2016 Mar 21;6:23353
pubmed: 26996336
Mol Cells. 2010 May;29(5):435-42
pubmed: 20396958
J Control Release. 2018 Apr 10;275:201-207
pubmed: 29474963
Cancer Lett. 2012 Jun 1;319(1):23-30
pubmed: 22182450
Cancer Discov. 2014 Sep;4(9):998-1013
pubmed: 25185190
Lancet Oncol. 2015 Aug;16(8):967-78
pubmed: 26179201
Sci Rep. 2017 Jul 26;7(1):6600
pubmed: 28747710
Biomaterials. 2017 Nov;145:233-241
pubmed: 28888113
Future Oncol. 2014 May;10(7):1311-27
pubmed: 24947267
Biosci Rep. 2016 Dec 9;36(6):
pubmed: 27803125
Clin Cancer Res. 2000 Mar;6(3):773-81
pubmed: 10741696
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Cell Chem Biol. 2017 Sep 21;24(9):1092-1100
pubmed: 28757181
Stem Cell Res Ther. 2019 Feb 7;10(1):51
pubmed: 30732645
Tissue Eng Part B Rev. 2014 Oct;20(5):365-80
pubmed: 24168395
Cell Stem Cell. 2019 Jan 3;24(1):12-24
pubmed: 30581078
Cell Tissue Res. 2006 Jun;324(3):411-22
pubmed: 16489443
CSH Protoc. 2008 Jun 01;2008:pdb.prot4478
pubmed: 21356842
Trends Biotechnol. 2013 Jun;31(6):347-54
pubmed: 23597659
PLoS One. 2018 Mar 15;13(3):e0194016
pubmed: 29543851
PLoS One. 2015 Aug 13;10(8):e0134346
pubmed: 26270481
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S810-6
pubmed: 26193962
N Engl J Med. 2019 Feb 7;380(6):569-579
pubmed: 30726695
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Metabolism. 2013 Jan;62 Suppl 1:S11-4
pubmed: 22999010
Biology (Basel). 2014 May 30;3(2):345-67
pubmed: 24887773
Neuro Oncol. 2012 May;14(5):574-83
pubmed: 22459127
Adv Drug Deliv Rev. 2014 Apr;69-70:29-41
pubmed: 24636868
Analyst. 2015 Jun 21;140(12):3910-20
pubmed: 25923379
Clin Cancer Res. 2017 Nov 1;23(21):6580-6591
pubmed: 28808038
Chin Med J (Engl). 2016 20th Oct;129(20):2469-2475
pubmed: 27748340
Adv Exp Med Biol. 2016;899:167-96
pubmed: 27325267
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Int J Cancer. 2015 Jan 1;136(1):204-11
pubmed: 24824628
PLoS One. 2015 Jun 19;10(6):e0130348
pubmed: 26090664
Cancer Discov. 2016 Feb;6(2):130-2
pubmed: 26851184
Front Physiol. 2017 Aug 22;8:605
pubmed: 28878686
Cancer Discov. 2017 May;7(5):462-477
pubmed: 28331002

Auteurs

Robson Amaral (R)

Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, 14040-903 Sao Paulo, Brazil.

Maike Zimmermann (M)

Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical School, Sacramento, CA 95817, USA.

Ai-Hong Ma (AH)

Department of Urology, UC Davis Comprehensive Cancer Center, University of California Davis Medical School, Sacramento, CA 95817, USA.

Hongyong Zhang (H)

Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical School, Sacramento, CA 95817, USA.

Kamilla Swiech (K)

Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, 14040-903 Sao Paulo, Brazil.

Chong-Xian Pan (CX)

Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical School, Sacramento, CA 95817, USA.
VA Northern California Health Care system, Mather, CA 95655, USA.
(Current address): Department of Faculty of Medicine, Harvard Medical School, West Roxbury, MA 02115, USA.

Classifications MeSH